Not applicableStudy completedNCT07211451What this trial is testingAxillary Nodal Burden in HER2+ and TNBCWho this might be right forBreast Cancer Gangnam Severance Hospital 1,571
Large-scale testing (Phase 3)Looking for participantsNCT05950945What this trial is testingTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerWho this might be right forBreast Cancer Daiichi Sankyo 250
Testing effectiveness (Phase 2)Study completedNCT02048059What this trial is testingANG1005 in Breast Cancer Patients With Recurrent Brain MetastasesWho this might be right forBreast CancerBrain Metastases Angiochem Inc 72
Not applicableStudy completedNCT04807595What this trial is testingEstimation of the Prevalence of HER2 Low and Describe the SoC, Treatment Patterns, and Outcome in Real-world Practice Among Unresectable and/or Metastatic Breast Cancer Patients With HER2 Low StatusWho this might be right forBreast Cancer AstraZeneca 798
Testing effectiveness (Phase 2)Study completedNCT00900627What this trial is testingPhase I/II AZD8931/Paclitaxel in Treatment of Advanced Solid Tumours (Phase I) and Advanced Breast Cancer (Phase II)Who this might be right forNeoplasmsBreast NeoplasmsBreast Cancer AstraZeneca 330
Large-scale testing (Phase 3)Active Not RecruitingNCT04494425What this trial is testingStudy of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast CancerWho this might be right forAdvanced or Metastatic Breast Cancer AstraZeneca 866
Testing effectiveness (Phase 2)Looking for participantsNCT07198724What this trial is testingERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast CancerWho this might be right forMetastatic Breast CancerHER2 Low Breast CarcinomaHER2-negative Breast Cancer+2 more Kristina A. Fanucci 65
Testing effectiveness (Phase 2)Enrolling By InvitationNCT06680596What this trial is testingDetecting Tumor DNA in the Blood of HR+/HER2-low Metastatic Breast Cancer Patients to Find Candidates for T-DXd TherapyWho this might be right forBreast Cancer MetastaticBreast Cancer Stage IV UNICANCER 80
Testing effectiveness (Phase 2)Looking for participantsNCT06439771What this trial is testingEvaluate the Efficacy, Safety and Pharmacokinetics of YL202 in Patients With BCWho this might be right forLocally Advanced or Metastatic Breast Cancer MediLink Therapeutics (Suzhou) Co., Ltd. 180
Early research (Phase 1)Looking for participantsNCT06331169What this trial is testingAnlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast CancerWho this might be right forBreast Cancer Fudan University 42
Testing effectiveness (Phase 2)Looking for participantsNCT06224673What this trial is testingARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast CancerWho this might be right forHER2 Low Breast CarcinomaTriple Negative Breast CancerHormone-receptor-positive Breast Cancer+1 more Laura Huppert, MD, BA 36
Testing effectiveness (Phase 2)Looking for participantsNCT07203729What this trial is testingThe Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral CrisisWho this might be right forHER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis Cancer Institute and Hospital, Chinese Academy of Medical Sciences 184
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07150208What this trial is testingT-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain MetastasisWho this might be right forBreast Cancer With Brain MetastasisHER2-low Expressing Breast Cancer Fudan University 140
Not applicableLooking for participantsNCT05945732What this trial is testingDESTINY Breast Respond HER2-(Ultra)Low EuropeWho this might be right forUnresectable Breast CancerMetastatic Breast CancerHER2-low Expressing Breast Cancer+1 more Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company 2,295
Testing effectiveness (Phase 2)UnknownNCT05845138What this trial is testingSHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.Who this might be right forBreast Cancer Suzhou Suncadia Biopharmaceuticals Co., Ltd. 116
Testing effectiveness (Phase 2)UnknownNCT05619016What this trial is testing[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid TumorsWho this might be right forEsophageal NeoplasmsGastric Neoplasms MalignantBreast Cancer+1 more Karolinska University Hospital 72
Early research (Phase 1)Ended earlyNCT02598427What this trial is testingIntrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast CancerWho this might be right forHER2 Positive Untreated Metastatic Breast CancerAsymptomatic or Low Symptomatic Brain Metastasis in Breast Cancer Kimberly Blackwell 1
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06975462What this trial is testingA Phase II Study of SHR-A1811 Combined With Radiotherapy in HER2-positive and HER2-low Breast Cancer Brain MetastasesWho this might be right forBreast Cancer Metastatic Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 30
Not applicableLooking for participantsNCT06210776What this trial is testingAssess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)Who this might be right forHER2-positive Breast CancerHER2-low Breast CancerBreast Cancer+1 more Daiichi Sankyo 800
Testing effectiveness (Phase 2)Looking for participantsNCT06533826What this trial is testingTReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXdWho this might be right forBreast CancerHER2-low Breast CancerMetastatic Breast Cancer+1 more Ana C Garrido-Castro, MD 357